白雲山(00874.HK)旗下3家藥企被國家醫保局點名通報
格隆匯8月10日丨白雲山(00874.HK)發佈公吿，公司得悉，在2022年8月9日，國家醫療保障局網站發佈了《關於天心製藥等3家企業虛增原料藥價格、虛抬藥價套取資金有關情況的通報》。《通報》所涉的三家企業為廣州白雲山醫藥集團股份有限公司白雲山製藥總廠(其為公司的分公司)、廣州白雲山天心製藥股份有限公司(其為公司的子公司)及廣州白雲山敬修堂藥業股份有限公司(其為公司的子公司)。
《通報》的主要內容如下：近期，相關政府部門對白雲山製藥總廠、天心製藥和敬修堂藥業三家企業開展了藥品虛高定價、套取資金的專項調查。《通報》指出，前述三家藥品生產企業為規避“兩票制”政策和監管，與下游50多家藥品代理商相互串通，對注射用頭孢硫脒等87種藥品採取虛高價格採購原料藥的方式套現。套現主要方式為在原料藥採購環節增加指定的“經銷商”，原料藥“經銷商”受藥品代理商實際控制，將低買高賣原料藥獲得的差價收入套現，轉移至藥品代理商。目前，天心製藥等3家企業已按要求在全國範圍內對所涉藥品進行價格整改(降價)，部分品規被停止採購。廣東省責令天心製藥等3家企業以及關聯的其他企業全面整改營銷模式，停止相關違規操作。此外，對涉嫌違紀、違法、犯罪的人員，有關部門正在依紀依法查處。
白雲山製藥總廠、天心製藥和敬修堂藥業涉及撤銷掛網(與《通報》有關而主動或被動停止向公立醫院銷售)產品的毛利合計約為人民幣0.15億元、與《通報》有關而降價銷售的產品的毛利合計約為人民幣3.20億元，作參考之用，上述數字佔公司2021年度經審計的毛利額比例分別約為0.12%及2.45%；2022年第一季度，以上三家企業涉及撤網產品毛利合計約為人民幣0.12億元、降價產品毛利合計約為人民幣1.02億元，作參考之用，上述數字佔公司2022年第一季度未經審計的毛利額的比例分別約為0.25%及2.13%。
公司高度重視本次《通報》事項，並已採取了一系列的整改措施。公司已經責成白雲山製藥總廠、天心製藥和敬修堂藥業停止與相關代理商、經銷商的合作，全面整改營銷模式，在全國範圍進行相關產品降價或撤網，對違規操作的行為絕不袒護，堅決處理，並已經對三家企業相關負責人予以免職或停職處理。今後，公司將堅決貫徹落實國家關於深化醫藥衞生體制改革的部署和政策，監督及督促下屬企業規範營銷模式，主動規範自身經營行為，自覺維護藥品流通秩序，依法依規做好生產經營工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
